Cytosurge AG

Cytosurge AG Leverage Cytosurge’s proprietary FluidFM® technology for precise, gentle single-cell manipulation and CRISPR engineering.

Our vision is to turn genetic designs into cures, bridging design and manufacturing > https://linktr.ee/cytosurge Cytosurge develops innovative research solutions using its proprietary FluidFM® technology for precise single-cell manipulation thereby fostering advancements in understanding cellular processes such as the ones that drive cancer. With the FluidFM OMNIUM platform, single-cell extracts, or “biopsies” can be taken from living cells, enabling live-sequencing and temporal transcriptomics analysis. Additionally, the CellEDIT Service provides high-quality genetically engineered cell lines through intra-nuclear injections of CRISPR RNPs. Cytosurge's vision is to unlock novel cures by translating next-generation genetic designs into living cells, enabling longer and healthier lives through precision gene engineering. The Company aims to implement advanced genetically engineered cell lines that bring next-generation therapies to fruition, bridging the gap between genetic design tools and manufacturing, and empowering genetic engineers to realize their visionary concepts.

08/10/2025

Dr. Gabriel Giger, 2025 Origins Federation PhD Prize winner, used to pioneer artificial endosymbiosis research at Zurich!

🎬 Watch Gabriel's interview to see how FluidFM's precise microinjection enabled him to:
✔️ Implant living bacteria into fungi
✔️ Track evolutionary adaptations in real-time
✔️ Create novel experimental systems
His Nature paper made an incredible impact:
📊 56K+ accesses | 99th percentile Altmetric score | 31 news outlets

"FluidFM allows us to explore live interactions between fungi and bacteria, offering new insights into microbial ecology dynamics." - Dr. Giger
Read the Nature paper 📄 https://go.nature.com/4jPwdYa
Watch more customer stories ▶️ https://bit.ly/4pMCxT3

We’ve been reconstructing dynamics from static snapshots, useful for discovery, but limited for causality. Pseudotime-ba...
02/10/2025

We’ve been reconstructing dynamics from static snapshots, useful for discovery, but limited for causality. Pseudotime-based inference can miss fast, rare, or non-monotonic transitions and depends on assumptions that may not fit your system. Complement your dataset with longitudinally paired datapoints from Live-seq to observe what actually happens in the very same cell.

What this unlocks:
• Within-cell causality and true trajectories
• Direct capture of rare states and fast switches
• Less reliance on inference-heavy models

If you’re studying drug resistance, differentiation, or stress responses, moving from snapshots to live-cell “movies” can turn a model into a mechanism.

Our application scientists are here to help. Reach out to book a consultation or join our 👇 QR codes below.

Ever wonder what the butterfly effect looks like in molecular biology?What if you could watch the "why" behind cellular ...
30/09/2025

Ever wonder what the butterfly effect looks like in molecular biology?
What if you could watch the "why" behind cellular changes, not just the "what"?

Live-seq lets you follow the same living cell over time, tracking which molecular events trigger major cellular transformations and which simply fade away. It's like live-cell imaging but for transcriptomics, revealing molecular changes before and after they happen.
Trace backwards from an outcome to understand its origins, or follow cells forward to predict their fate.

Instead of seeing only the final storm, you witness the entire chain reaction: from tiny molecular flutter to dramatic cellular transformation.
The shift is profound: from correlation to causation. From descriptive to predictive.
Powered by OMNIUM, reveals the hidden connections in single-cell biology, without sacrificing the cells you study.

Ready to see the butterfly that starts the storm?

25/09/2025

Following , we celebrate the researchers pushing the boundaries of cancer understanding. At Institut Curie, breakthrough science is happening at the single-cell level.
Epithelial–mesenchymal transition ( ) drives cancer metastasis, but it's dynamic and heterogeneous. Traditional endpoint scRNA-seq offers snapshots, useful, but can't reveal which single cells will transition or when.
+ are changing that.

Read our newest blog featuring Dr. Leanne de Koning (Single Cell Initiative) and PhD student Margot Le Bot at Institut Curie (supervised by Drs. Benoît Sorre and Leïla Perié), and learn how they apply Live-seq to EMT in triple-negative breast cancer using FluidFM biopsies and full-life experiments without sacrificing cells, and exploring chemotherapy responses, MET, and future multi-omics from the same cell.

Dive into the conversation: https://bit.ly/3Iopu9G

📢 Cytosurge and Lexogen GmbH announce that their integrated Live-seq workflow is now available to academic researchers a...
24/09/2025

📢 Cytosurge and Lexogen GmbH announce that their integrated Live-seq workflow is now available to academic researchers and industry partners worldwide.
This breakthrough enables labs of any size to repeatedly sequence the same living cells, directly observing how shapes cellular behavior over time.

Researchers are invited to an upcoming and encouraged to apply for Cytosurge’s Live-seq Access Program, which offers proof-of-principle studies for selected projects.💻

LINKS in the announcement 👉https://cytosurge.com/blog/press-release-13/cytosurge-lexogen-announce-live-seq-workflow-readiness-89?utm_source=linkedin&utm_medium=social_organic&utm_campaign=Liveseq_update

22/09/2025

From collaboration to publication, a success story worth revisiting.
Earlier this year, Nature Genetics published "Gene regulation by convergent promoters" (Wiechens et al., Jan 2025), a landmark study led by Martin Fischer and Steve Hoffmann that challenges long-held views on transcriptional interference and reveals convergent promoters ( ) as dynamic regulators of gene expression.🧬

Back in 2024, our Service partnered with Dr. Kanstantsin Siniuk (Leibniz Institute on Aging – FLI) to support this important work. We generated an independent knockout of a p53 binding site, providing the crucial validation reviewers requested through vector-free, intra-nuclear CRISPR delivery with .🎯

It's collaborations like these that drive scientific breakthroughs forward.🚀

Explore the full collaboration story and paper: https://bit.ly/4g8Jrfy

18/09/2025

Listen to Dr. Annemarie M. Voorberg-van der Wel as she shares how she and Dr. Anne Marie Zeeman are pioneering new approaches to parasite–host interactions at BPRC, aiming to help the 240+ million people affected by worldwide, powered by the platform. 🔬

The challenge ⚠️ hypnozoites, the elusive, dormant liver stages behind relapsing malaria. To decode dormancy/reactivation, capture parasite–host crosstalk, and reduce animal use, BPRC turned to FluidFM for single-cell precision.

Why OMNIUM matters in their lab:
• Perturb + sample the same cell: nanoinjection/extraction in hepatocytes and hypnozoites to test hypotheses, then read out molecular consequences
• Longitudinal insight: Live seq tracks transcriptomes through dormancy and reactivation
• Direct hypnozoite access: visualize rare dormant forms and run relapse biology assays
• Miniaturized in vitro: reduce animal use and speed method/compound testing

How would you apply this technology in your research? Share your thoughts below!

Read the full story 📖 https://bit.ly/46hs5dm
Watch more customer stories: Full YouTube playlist ▶️ https://bit.ly/4gwzbQ4

16/09/2025

Be the first to hear about new advances in single-cell analysis, upcoming webinars, free events, and conferences: 🧬✨
• Follow us on social for real-time updates
• Visit our website for insights and event listings
• Subscribe to our newsletter for exclusive content: https://www.linkedin.com/newsletters/fluidfm-update-newsletter-7120776447593431041/
Discover how we’re transforming single-cell research. Connect, learn, and meet us!

11/09/2025

Throwback to our summer event. Our team swapped lab benches and desks for puzzles, trains, and lake views, kicking off at Boda Borg Zürich for questing, then by rail to Rapperswil and across the water to Insel Ufnau for a relaxed dinner before a sunset ferry back to Pfäffikon SZ. The best part? Time together: laughs, conversations, and the kind of shared moments that make collaboration smoother when we’re back at work. Thanks to everyone who joined and made it one to remember. 📸🌅

· Chapter 4: Overcome the “hard” in hard-to-transfect cellsWhen viral delivery, lipofection, or electroporation fall s...
08/09/2025

· Chapter 4: Overcome the “hard” in hard-to-transfect cells

When viral delivery, lipofection, or electroporation fall short, ’s FluidFM-based intra nuclear injection offers a different path: force-controlled nanopipettes place CRISPR RNPs directly into the nucleus of a single cell, gently, precisely.

What does this unlock? Carousel below👇

Have a stubborn cell line? Let us know which ones you struggle with!

04/09/2025

Dr. Young Hun Kim shares her experience establishing and operating FluidFM at the Molecular Cytology Core Facility during her time at Memorial Sloan Kettering Cancer Center, NY. 👇🎬

💬"Because our FluidFM system was housed in a core facility, we could assist many researchers. In particular, it allowed us to extract mRNA from live cells to study gene expression changes without causing cell damage. This precision opened new doors for drug response studies at the single-cell level."

More customer stories ▶️ https://bit.ly/4mX11an

Trouble with editing efficiency or cell outgrowth in prostate cancer lines (PC-3, LNCaP)? 🧬 You’re not alone. Traditiona...
01/09/2025

Trouble with editing efficiency or cell outgrowth in prostate cancer lines (PC-3, LNCaP)? 🧬 You’re not alone. Traditional workflows can be slow and inconsistent.

Meet , powered by :
✅ Direct intra-nuclear RNP delivery — force-controlled and precise stoichiometry
✅ Vector-free — no viruses, no random integration
✅ Gentle yet effective — preserves viability in sensitive cell lines
✅ Reliable — high efficiency, low off-target risk

🎯 Whether you’re studying metastasis, drug resistance, or gene function, CellEDIT helps you get clean edits without the headache.
Book a consultation with Dr. Gorka Santos Fe to streamline your CRISPR editing.: https://linktr.ee/celledit

Adresse

Sägereistrasse 25
Glattbrugg
8152

Öffnungszeiten

Montag 09:00 - 18:00
Dienstag 09:00 - 18:00
Mittwoch 09:00 - 18:00
Donnerstag 09:00 - 18:00
Freitag 09:00 - 18:00

Telefon

+41445331450

Webseite

Benachrichtigungen

Lassen Sie sich von uns eine E-Mail senden und seien Sie der erste der Neuigkeiten und Aktionen von Cytosurge AG erfährt. Ihre E-Mail-Adresse wird nicht für andere Zwecke verwendet und Sie können sich jederzeit abmelden.

Verknüpfungen

Teilen

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram

Our Story

Founded in 2009, Cytosurge AG successfully develops, manufactures and distributes cutting-edge and unique high-precision nanotechnology instruments as well as robotic systems based on its patented FluidFM® technology.

Whether via the FluidFM ADD-ON, a powerful upgrade solution for your AFM, the FluidFM BOT, a fully integrated system for cell research, or via the award-winning FluidFM µ3Dprinter for 3D metal printing at the micrometre scale, Cytosurge provides leading-edge tools and processes to those who need or want to go beyond current technological boundaries.

FluidFM – GO BEYOND.